Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by newer disease-modifying therapies, a study shows.

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

Salesforce added 6,000 Agentforce customers in one quarter, hitting $540M in revenue—challenging the AI bubble narrative with ...